TENX - facing resistance for the 3rd time in the short period

Company currently in the process of development of levosimendan for Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Efforts included a successful pre-IND meeting with the FDA in April 2018, which allowed the existing Phase II clinical protocol to be used for PH-HFpEF. During the summer and fall, the company identified clinical trial sites, obtained approvals from institutional review boards (IRBs) and executed on contracting and scheduling. Prior to year end, the first site was activated and the first patient in the Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF or HELP trial was enrolled in March 2019. The company also closed a $10 million capital raise in December, providing funds in support of the HELP trial which should be sufficient to complete the end of Phase II meeting.